Home > A. Molecular pathology > IDHs
IDHs
Monday 12 July 2010
Isocitrate dehydrogenase
Types
Pathology
IDH1 and IDH2 somatic mutations in :
- glial tumors : lox-grade flioma and glioblastoma
- spindle cell hemangioma
- cholangiocarcinoma
- chondrosarcomas
- AML acute myeloid leukemia
- MDS myelodysplasia / myelodysplastic syndromes
References
Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma? Kloosterhof NK, Bralten LB, Dubbink HJ, French PJ, van den Bent MJ. Lancet Oncol. 2010 Jul 6. PMID: 20615753
IDH1 mutation identified in human melanoma. Lopez GY, Reitman ZJ, Solomon D, Waldman T, Bigner DD, McLendon RE, Samuels Y, Yan H. Biochem Biophys Res Commun. 2010 Jul 2. PMID: 20603105
Proteomic analysis of hyphae-specific proteins that are expressed differentially in cakem1/cakem1 mutant strains of Candida albicans. Lee KH, Kim SY, Jung JH, Kim J. J Microbiol. 2010 Jun;48(3):365-71. PMID: 20571955
IDH1 and IDH2 Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With NPM1 Mutation Without FLT3 Internal Tandem Duplication. Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Krönke J, Bullinger L, Späth D, Kayser S, Zucknick M, Götze K, Horst HA, Germing U, Döhner H, Döhner K. J Clin Oncol. 2010 Jun 21. PMID: 20567020
Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia (AML): prevalence and prognostic value. Abbas S, Lugthart S, Kavelaars FG, Schelen A, Koenders J, Zeilemaker A, van Putten WJ, Rijneveld A, Löwenberg B, Valk PJ. Blood. 2010 Jun 10. PMID: 20538800
Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. Reitman ZJ, Yan H. J Natl Cancer Inst. 2010 Jul 7;102(13):932-41. PMID: 20513808
Glioma-derived mutations in IDH: from mechanism to potential therapy. Fu Y, Huang R, Du J, Yang R, An N, Liang A. Biochem Biophys Res Commun. 2010 Jun 25;397(2):127-30. PMID: 20510884
IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Tefferi A, Lasho TL, Abdel-Wahab O, Guglielmelli P, Patel J, Caramazza D, Pieri L, Finke CM, Kilpivaara O, Wadleigh M, Mai M, McClure RF, Gilliland DG, Levine RL, Pardanani A, Vannucchi AM. Leukemia. 2010 May 27. PMID: 20508616
IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Thol F, Weissinger EM, Krauter J, Wagner K, Damm F, Wichmann M, Goehring G, Schumann C, Bug G, Ottmann O, Hofmann WK, Schlegelberger B, Ganser A, Heuser M. Haematologica. 2010 May 21. PMID: 20494930
WHO-defined ’myelodysplastic syndrome with isolated del(5q)’ in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations. Patnaik MM, Lasho TL, Finke CM, Gangat N, Caramazza D, Holtan SG, Pardanani A, Knudson RA, Ketterling RP, Chen D, Hoyer JD, Hanson CA, Tefferi A. Leukemia. 2010 May 20. PMID: 20485371
Molecular signatures classify astrocytic gliomas by IDH1 mutation status. Toedt G, Barbus S, Wolter M, Felsberg J, Tews B, Blond F, Sabel MC, Hofmann S, Becker N, Hartmann C, Ohgaki H, von Deimling A, Wiestler OD, Hahn M, Lichter P, Reifenberger G, Radlwimmer B. Int J Cancer. 2010 May 12. PMID: 20473936
Prognostic markers in gliomas. Labussiere M, Wang XW, Idbaih A, Ducray F, Sanson M. Future Oncol. 2010 May;6(5):733-9. PMID: 20465388
Detection of IDH1 and IDH2 mutations by fluorescence melting curve analysis as a diagnostic tool for brain biopsies. Horbinski C, Kelly L, Nikiforov YE, Durso MB, Nikiforova MN. J Mol Diagn. 2010 Jul;12(4):487-92. PMID: 20431032
All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Labussière M, Idbaih A, Wang XW, Marie Y, Boisselier B, Falet C, Paris S, Laffaire J, Carpentier C, Crinière E, Ducray F, El Hallani S, Mokhtari K, Hoang-Xuan K, Delattre JY, Sanson M. Neurology. 2010 Jun 8;74(23):1886-90. PMID: 20427748
Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Thol F, Damm F, Wagner K, Göhring G, Schlegelberger B, Hoelzer D, Lübbert M, Heit W, Kanz L, Schlimok G, Raghavachar A, Fiedler W, Kirchner H, Heil G, Heuser M, Krauter J, Ganser A. Blood. 2010 Apr 26. PMID: 20421455
IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms. Pardanani A, Lasho TL, Finke CM, Mai M, McClure RF, Tefferi A. Leukemia. 2010 Jun;24(6):1146-51. PMID: 20410924
Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Kosmider O, Gelsi-Boyer V, Slama L, Dreyfus F, Beyne-Rauzy O, Quesnel B, Hunault-Berger M, Slama B, Vey N, Lacombe C, Solary E, Birnbaum D, Bernard OA, Fontenay M. Leukemia. 2010 May;24(5):1094-6. PMID: 20376084
IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Marcucci G, Maharry K, Wu YZ, Radmacher MD, Mrózek K, Margeson D, Holland KB, Whitman SP, Becker H, Schwind S, Metzeler KH, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Caligiuri MA, Larson RA, Bloomfield CD. J Clin Oncol. 2010 May 10;28(14):2348-55. PMID: 20368543
IDH1 and IDH2 mutations in gliomas and the associated induction of hypoxia-inducible factor and production of 2-hydroxyglutarate. Komotar RJ, Starke RM, Sisti MB, Connolly ES. Neurosurgery. 2010 Apr;66(4):N20-1. PMID: 20305482
IDH1 and IDH2: not your typical oncogenes. Reitman ZJ, Parsons DW, Yan H. Cancer Cell. 2010 Mar 16;17(3):215-6. PMID: 20227034
Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer. Murugan AK, Bojdani E, Xing M. Biochem Biophys Res Commun. 2010 Mar 12;393(3):555-9. PMID: 20171178
The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, Cross JR, Fantin VR, Hedvat CV, Perl AE, Rabinowitz JD, Carroll M, Su SM, Sharp KA, Levine RL, Thompson CB. Cancer Cell. 2010 Mar 16;17(3):225-34. PMID: 20171147
IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJ, Wesseling P, Frenay M, Tijssen CC, Lacombe D, Idbaih A, van Marion R, Kros JM, Dinjens WN, Gorlia T, Sanson M. Clin Cancer Res. 2010 Mar 1;16(5):1597-604. PMID: 20160062
Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. Gross S, Cairns RA, Minden MD, Driggers EM, Bittinger MA, Jang HG, Sasaki M, Jin S, Schenkein DP, Su SM, Dang L, Fantin VR, Mak TW. J Exp Med. 2010 Feb 15;207(2):339-44. PMID: 20142433
Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing. Felsberg J, Wolter M, Seul H, Friedensdorf B, Göppert M, Sabel MC, Reifenberger G. Acta Neuropathol. 2010 Apr;119(4):501-7. PMID: 20131059
Mutations of the metabolic genes IDH1, IDH2, and SDHAF2 are not major determinants of the pseudohypoxic phenotype of sporadic pheochromocytomas and paragangliomas. Yao L, Barontini M, Niederle B, Jech M, Pfragner R, Dahia PL. J Clin Endocrinol Metab. 2010 Mar;95(3):1469-72. PMID: 20130071
Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. Green A, Beer P. N Engl J Med. 2010 Jan 28;362(4):369-70. PMID: 20107228
Mutant metabolic enzymes are at the origin of gliomas. Yan H, Bigner DD, Velculescu V, Parsons DW. Cancer Res. 2009 Dec 15;69(24):9157-9. PMID: 19996293
IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Dubbink HJ, Taal W, van Marion R, Kros JM, van Heuvel I, Bromberg JE, Zonnenberg BA, Zonnenberg CB, Postma TJ, Gijtenbeek JM, Boogerd W, Groenendijk FH, Smitt PA, Dinjens WN, van den Bent MJ. Neurology. 2009 Nov 24;73(21):1792-5. PMID: 19933982
Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues. Horbinski C, Kofler J, Kelly LM, Murdoch GH, Nikiforova MN. J Neuropathol Exp Neurol. 2009 Dec;68(12):1319-25.PMID: 19915484
31.
Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas. Gaal J, Burnichon N, Korpershoek E, Roncelin I, Bertherat J, Plouin PF, de Krijger RR, Gimenez-Roqueplo AP, Dinjens WN. J Clin Endocrinol Metab. 2010 Mar;95(3):1274-8. PMID: 19915015
IDH1 and IDH2 hotspot mutations are not found in canine glioma. Reitman ZJ, Olby NJ, Mariani CL, Thomas R, Breen M, Bigner DD, McLendon RE, Yan H. Int J Cancer. 2010 Jul 1;127(1):245-6. PMID: 19877121
Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Sonoda Y, Kumabe T, Nakamura T, Saito R, Kanamori M, Yamashita Y, Suzuki H, Tominaga T. Cancer Sci. 2009 Oct;100(10):1996-8. PMID: 19765000
Novel insights into the pathogenesis of gliomas based on large-scale molecular profiling approaches. Riemenschneider MJ, Reifenberger G. Curr Opin Neurol. 2009 Sep 5. PMID: 19741528
Diagnostic and prognostic markers in gliomas. Ducray F, El Hallani S, Idbaih A. Curr Opin Oncol. 2009 Nov;21(6):537-42. PMID: 19667985
Advances in the genetics of glioblastoma: are we reaching critical mass? Purow B, Schiff D. Nat Rev Neurol. 2009 Aug;5(8):419-26. PMID: 19597514
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W, Weller M, Herold-Mende C, Unterberg A, Jeuken JW, Wesseling P, Reifenberger G, von Deimling A. Acta Neuropathol. 2009 Oct;118(4):469-74. PMID: 19554337
Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Korshunov A, Meyer J, Capper D, Christians A, Remke M, Witt H, Pfister S, von Deimling A, Hartmann C. Acta Neuropathol. 2009 Sep;118(3):401-5. PMID: 19543740
IDH1 and IDH2 mutations in gliomas. Ducray F, Marie Y, Sanson M. N Engl J Med. 2009 May 21;360(21):2248-9; author reply 2249. PMID: 19469031
IDH1 and IDH2 mutations in gliomas. De Carli E, Wang X, Puget S. N Engl J Med. 2009 May 21;360(21):2248; author reply 2249. PMID: 19458374
42.
Mutations of IDH1 and IDH2 are not detected in brain metastases of colorectal cancer. Holdhoff M, Parsons DW, Diaz LA Jr. J Neurooncol. 2009 Sep;94(2):297. PMID: 19350208
IDH1 and IDH2 mutations in gliomas. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD. N Engl J Med. 2009 Feb 19;360(8):765-73. PMID: 19228619